RobertAlanBrodskyMD

Hematologic Oncology

Johns Hopkins Family Professor of Medicine and Oncology, Johns Hopkins University School of Medicine; Director, Division of Hematology President, American Society of Hematology 2023

Join to view full profile

Dr. Brodsky is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Brodsky's full profile

Already have an account?

Office
401 North Broadway Street
Weinberg BLDG
Baltimore, MD 21287
Phone+1 410-955-8964

Fax+1 410-367-2194

Summary

Dr. Robert Brodsky is a hematologist in Baltimore, MD and is affiliated with multiple hospitals in the area, including Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center. He received his medical degree from Drexel University College of Medicine and has been in practice 28 years. He specializes in hematology and is experienced in hemolytic anemias, PNH, complement-mediated diseases, aplastic anemia, and bone marrow transplantation.

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1994 - 1997
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1991 - 1994
Vanderbilt University Medical CenterResidency, Internal Medicine, 1989 - 1991
Drexel University College of MedicineClass of 1989, MD

Certifications & Licensure

MD State Medical License 1993 - 2026
TN State Medical License 1990 - 1995
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Top Doctors:Baltimore Area Castle Connolly, 2012-2024
America's Top Doctors Castle Connolly, 2012-2023
America's Top Doctors for Cancer Castle Connolly, 2012-2023
Top Doctors:Washington-Baltimore Castle Connolly, 2012-2023
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Join now to see all

Clinical Trials

High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis Start of enrollment: 2010 Nov 01
Withdrawn
Phase 2
Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry Start of enrollment: 2004 Oct 29
Recruiting
Bone Marrow Transplant Trial for Patients With Refractory Severe Aplastic Anemia Start of enrollment: 2011 Jun 01
Terminated
Phase 2
Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia Start of enrollment: 2014 Aug 01
Completed
Phase 2
A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH Start of enrollment: 2015 Feb 23
Completed
Phase 1
ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Start of enrollment: 2016 Dec 12
Completed
Phase 3
Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507) Start of enrollment: 2017 Oct 03
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Complement biosensors identify a classical pathway stimulus in complement-mediated thrombotic microangiopathy.
Michael A Cole, Nikhil Ranjan, Gloria F Gerber, Xiang-Zuo Pan, Daniel Flores-Guerrero
Blood. 2024-12-12
Advanced practice providers in hematology: actionable findings from national paired APP and physician surveys.
Ariela L Marshall, Leah E Masselink, Peter A Kouides, Faith E Davies, Azam Farooqui
Blood Advances. 2024-03-12
2 citations
Uniform conditioning regardless of donor in bone marrow transplantation for severe aplastic anemia.
Amy E DeZern, Marianna Zahurak, Richard J Jones, Robert A Brodsky
Haematologica. 2024-02-01

Abstracts/Posters

Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease: BMT CTN Protocol 1507
Robert A. Brodsky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Breakthrough Hemolysis in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: Results of a 52-Week Extension from Two Phase 3 Studies
Robert A. Brodsky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Mechanistic Evaluation of Efficacy Using Biomarkers of the Oral, Small Molecule Factor D Inhibitor, Danicopan (ACH-4471), in Untreated Patients with Paroxysmal Nocturn...
Robert A. Brodsky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Path to Cure: Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Treatment-Na¥ve and Refractory Severe Aplastic Anemia (...
Robert A. Brodsky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment
Robert A. Brodsky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Cancer Medicine and Hematology
Harvard Medical School, Boston, Massachusetts - 9/30/2012

Press Mentions

CAR-Ts and BiTEs: The Cost and Efficacy EquationAugust 28th, 2024
CAR-Ts and BiTEs: The Cost and Efficacy EquationAugust 26th, 2024
The Thorny History of Sickle Cell AnemiaJanuary 25th, 2023
Join now to see all

Grant Support

Complementopathies: genotype and phenotypeNHLBI2016–Present
GPI Anchor Deficiency In HematopoiesisNational Cancer Institute2008–2012
Training Program In HematologyNational Heart, Lung, And Blood Institute2006–2011
Pathophysiology Of PNHNational Cancer Institute2002
Mechanisms Of Clonal Dominance In PNHNational Cancer Institute1998–2000